Coeptis Therapeutics Has Completed The Exclusive License Of Key Assets From Deverra Therapeutics Related To Its Proprietary Allogeneic Stem Cell Expansion And Directed Differentiation Platform; Coeptis Paid Approximately $570K In Cash And Issued 4M Shares
Portfolio Pulse from Benzinga Newsdesk
Coeptis Therapeutics has acquired key assets from Deverra Therapeutics related to its proprietary allogeneic stem cell expansion and directed differentiation platform. The deal was completed with a payment of approximately $570K in cash and the issuance of 4M shares.
August 17, 2023 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Coeptis Therapeutics' acquisition of key assets from Deverra Therapeutics could potentially enhance its product portfolio and future revenue streams.
The acquisition of these key assets could potentially enhance Coeptis Therapeutics' product portfolio and provide new revenue streams in the future. This could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100